



## **Dr. Lewis to Participate as Chairman and Invited Lecturer at the 2nd Annual International Conference on Drug Discovery & Therapy, Dubai, UAE**

NEW YORK, Jan 27, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, has been invited to participate at the 2<sup>nd</sup> International Conference on Drug Discovery and Therapy in Dubai, United Arab Emirates as:

- Chairman of Translational Biomedical Research
- Chairman of one of four Plenary Sessions
- An Invited Lecturer (Tuesday, February 2<sup>nd</sup>): **Translational Research in Cancer; Programs of Multi-Institutional University and Industry Collaboration in Drug Discovery and Development**

Presenters: Jonathan Lewis (Ziopharm), Robert F. Struck (Southern Research Institute -SRI), Larry Norton (Sloan-Kettering and Cornell University)

The conference will be held at the Dubai Men's College and will take place February 1<sup>st</sup> through the 4<sup>th</sup> 2010.

### **About ZIOPHARM Oncology, Inc.:**

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (Zymafos<sup>TM</sup> or ZIO-201) references a novel composition (tris formulation) that comprises the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used DNA-alkylating drugs used to treat cancers. Palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. It may also have other advantages. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting with the Company having reported interim positive results in late 2009; a registration trial in the same setting is expected to initiate following U.S. Food and Drug Administration (FDA) review in the first half of this year. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.

Darinaparsin (Zinapar<sup>TM</sup> or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. The Company has reported favorable results from a Phase II trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), at the American Society of Clinical Oncology (ASCO) in May of 2009. Supported by these data, the Company expects to advance into a registration trial in peripheral T-cell lymphoma following FDA review. Phase I trials with the oral form are ongoing in both hematological malignancies and solid tumors.

Indibulin (Zybulin<sup>TM</sup> or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. In addition, indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I trials in cancer patients, oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. Most recently, results of oral indibulin in combination with oral capecitabine (Xeloda<sup>(R)</sup>) were presented at last year's American Society of Clinical Oncology (ASCO) along with the preclinical findings of a novel dosing schedule conducted under the direction of Dr. Larry Norton; employing this dosage schedule, the Company expects to initiate a Phase I study early this year in breast cancer patients with the breast team at Memorial Sloan Kettering.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at [www.ziopharm.com](http://www.ziopharm.com).

ZIOP-G

**Forward-Looking Safe Harbor Statement:**

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.

SOURCE: ZIOPHARM Oncology, Inc.

S.A. Noonan Communications, LLC

**Susan Noonan**, 212-966-3650

[susan@sanoonan.com](mailto:susan@sanoonan.com)

or

Rx Communications Group

**Eric Goldman - Media**, 917-322-2563

[egoldman@rxir.com](mailto:egoldman@rxir.com)

or

ZIOPHARM Oncology, Inc.

**Tyler Cook**, 617-259-1982

[tcook@ziopharm.com](mailto:tcook@ziopharm.com)

Copyright Business Wire 2010